JNJ-79635322

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Multiple MyelomaRelapsed or Refractory Multiple Myeloma

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

1

Empliciti

Bristol-Myers Squibb

Phase 3

452

Fludara

Sanofi

Phase 3

473

Ninlaro

Takeda

Phase 3

184

Keytruda

Merck & Co.

Phase 3

175

Venclexta

AbbVie

Phase 3

176

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

427

Biaxin

AbbVie

Phase 3

158

Opdivo

Bristol-Myers Squibb

Phase 3

119

Azatiq

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

2310

Elranatamab

Pfizer

Phase 3

27Show 29 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Multiple Myeloma4 trials

A Phase 2, Open-label Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody

Recruiting·Johnson & Johnson·Phase 2·NCT07266441·157 enrolled

A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti CD38 Antibody

Recruiting·Johnson & Johnson·Phase 3·NCT07258511·400 enrolled

A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide

Recruiting·Johnson & Johnson·Phase 3·NCT07518186·700 enrolled

Show 1 more trial

A Phase 1b Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

Recruiting·Johnson & Johnson·Phase 1·NCT06768489·240 enrolled

Relapsed or Refractory Multiple Myeloma1 trial

Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis

Recruiting·Johnson & Johnson·Phase 1·NCT05652335·180 enrolled

Unspecified1 trial

GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

Recruiting·UUniversity of Heidelberg Medical Center·Phase 2·NCT05695508·160 enrolled

Details

Drug Info

Related News